TYMLOS® (abaloparatide) injection
Postmenopausal osteoporosis at high risk for fracture
ApprovedActive
Key Facts
Indication
Postmenopausal osteoporosis at high risk for fracture
Phase
Approved
Status
Active
Company
About Radius Health
Radius Health is a U.S.-based, commercial-stage biopharma company that has established itself in the bone health market with its lead product, TYMLOS, an anabolic agent for osteoporosis. The company expanded its portfolio in 2023 by in-licensing BINOSTO, an oral effervescent bisphosphonate, and is actively seeking further partnership and growth opportunities. In 2024, Radius Health became part of Paratek Pharmaceuticals, a strategic move that likely aims to combine resources and pipelines for enhanced scale and commercial reach in specialty therapeutics.
View full company profile